Kiniksa Pharmaceuticals Ltd (KNSA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kiniksa Pharmaceuticals Ltd (KNSA) has a cash flow conversion efficiency ratio of 0.083x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($50.20 Million) by net assets ($605.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Kiniksa Pharmaceuticals Ltd's balance sheet to measure how much of total assets are equity-financed.
Kiniksa Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Kiniksa Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Kiniksa Pharmaceuticals Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Kiniksa Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kiniksa Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lisi S.A
PA:FII
|
0.057x |
|
Zhejiang Kaishan Compressor
SHE:300257
|
0.028x |
|
Fujian Sunner Development Co Ltd
SHE:002299
|
0.145x |
|
SES S.A
F:SES
|
N/A |
|
MGE Energy Inc
NASDAQ:MGEE
|
0.060x |
|
Liechtensteinische Landesbank AG
SW:LLBN
|
0.034x |
|
Shanghai Lingang Holdings Co Ltd A
SHG:600848
|
-0.002x |
|
ARIS MNG.CORP.
F:ZP1
|
0.101x |
Annual Cash Flow Conversion Efficiency for Kiniksa Pharmaceuticals Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of Kiniksa Pharmaceuticals Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Kiniksa Pharmaceuticals Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $567.61 Million | $25.69 Million | 0.045x | -22.76% |
| 2024-12-31 | $438.44 Million | $25.69 Million | 0.059x | +93.31% |
| 2023-12-31 | $438.84 Million | $13.30 Million | 0.030x | +106.77% |
| 2022-12-31 | $396.15 Million | $5.81 Million | 0.015x | +102.15% |
| 2021-12-31 | $185.04 Million | $-126.30 Million | -0.683x | -55.94% |
| 2020-12-31 | $311.94 Million | $-136.53 Million | -0.438x | +37.70% |
| 2019-12-31 | $225.42 Million | $-158.37 Million | -0.703x | -142.18% |
| 2018-12-31 | $279.27 Million | $-81.01 Million | -0.290x | -151.82% |
| 2017-12-31 | $-89.71 Million | $-50.22 Million | 0.560x | -34.12% |
| 2016-12-31 | $-25.73 Million | $-21.87 Million | 0.850x | -- |
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-3… Read more